You just read:

SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

News provided by

SillaJen, Inc.

Jul 21, 2017, 00:00 ET